Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a clinical syndrome characterized by tachyarrhythmias that originate from or conduct through the atria or atrioventricular (AV) node, typically presenting with an abrupt onset and termination ^[30]D5. While the term broadly encompasses any arrhythmia arising above the bundle of His, it is most frequently used to describe paroxysmal supraventricular tachycardia (PSVT), which affects between 168 to 332 per 100,000 individuals ^[30]D5. These arrhythmias are generally benign but can lead to tachycardia-mediated cardiomyopathy in approximately 1% of cases if left untreated ^[30]D5.

Synonyms and Abbreviations

• PSVT: Paroxysmal Supraventricular Tachycardia
• SVT: Supraventricular Tachycardia
• PAT: Paroxysmal Atrial Tachycardia (historical term)
• Narrow-complex tachycardia: A common clinical descriptor (though SVT may present with wide complexes in the setting of aberrancy)

Classification and Mechanisms

SVT is classified by its electrophysiological mechanism and anatomical circuit. The three most common forms of PSVT are AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT) involving an accessory pathway, and atrial tachycardia (AT) ^[22]A1a.

Nomenclature and Clinical Variants

Specific variants are defined by their conduction properties and clinical associations. Atypical fast-slow (F/S) AVNRT is a distinct subtype incorporating a "superior" slow pathway located above the Koch triangle, often requiring ablation near the His bundle ^[16]C4. In pediatric populations, postoperative junctional ectopic tachycardia (JET) is a hemodynamically significant variant occurring after congenital heart surgery ^[23]A1a.

Clinical significance is often driven by the presence of pre-excitation. Wolff-Parkinson-White (WPW) syndrome refers to the combination of an accessory pathway (pre-excitation on ECG) and symptomatic SVT; in asymptomatic patients with pre-excitation, the risk of malignant atrial fibrillation (shortest RR interval ≤250 ms) ranges from 0% to 9% ^[1]A1a[2]A1a.

Pearl: SVT is a clinical umbrella, not a single diagnosis; identifying the specific mechanism (AVNRT vs. AVRT vs. AT) is essential because it dictates the success rate of definitive catheter ablation, which exceeds 94% across most subtypes ^[30]D5.

Scope and interpretation

Contemporary evidence indicates that supraventricular tachycardia (SVT) is observed across the lifespan and in diverse clinical settings, but the supplied studies do not provide a single population-based estimate of overall SVT prevalence or incidence. Available evidence instead describes SVT or related supraventricular arrhythmias in emergency-care, ambulatory-monitoring, postoperative, critical-care, inflammatory-disease, pregnancy, pediatric, fetal, and inherited-syndrome populations. Accordingly, observed frequencies are strongly influenced by case definition, monitoring duration, clinical setting, and whether atrial fibrillation, atrial flutter, atrial tachycardia, junctional tachycardia, and non-sustained SVT are grouped together. ^{[49]B2b[47]A1b[149][152]C[58]B2b}

Age, sex, and clinical presentation

SVT occurs in both children and adults. Pediatric studies have evaluated emergency encounters in patients aged 0–18 years, excluding congenital heart disease in the analyzed cohorts, while postoperative congenital-heart studies have included infants and children with ectopic atrial tachycardia or junctional ectopic tachycardia. ^{[153][156]C[23]A1a} In adults with palpitations and structurally normal hearts, extended 24–96-hour Holter monitoring was used to identify supraventricular ectopy and tachyarrhythmias, illustrating that detection depends on the duration and context of ambulatory monitoring. ^[49]B2b

Sex-related differences may influence recognition and presentation. A tertiary emergency-department study specifically examined women and men with electrocardiographically confirmed SVT, including differences in symptoms, treatment, follow-up, and etiologic factors; the study focused on symptoms beyond palpitations, including anxiety, panic, and nausea. ^[150] Pregnancy is another clinically relevant setting: a systematic review and meta-analysis evaluated maternal arrhythmias in relation to preeclampsia, stillbirth, preterm delivery, and small-for-gestational-age birth, with analyses by arrhythmia type. ^[45]B2a The available abstract reports increasing maternal-arrhythmia prevalence with advanced maternal age but does not establish a specific SVT incidence estimate or causal relationship. ^[45]B2a

Acquired and behavioral associations

Cannabis exposure is a potential modifiable association. A systematic review and meta-analysis of large population studies evaluated cannabis use in relation to atrial arrhythmias, including atrial fibrillation, atrial flutter, atrial tachycardia, and SVT. The biological rationale considered in the review includes delta-9-tetrahydrocannabinol-related sympathetic stimulation and endothelial dysfunction; however, the supplied evidence does not provide the pooled effect estimate, and association should not be interpreted as proof of causation. ^[44]B2a

Sleep may also modify arrhythmic susceptibility. A secondary analysis of the CRAVE randomized 14-day case-crossover trial investigated whether sleep duration, sleep disturbances, and self-rated sleep quality predicted next-day premature atrial contractions, premature ventricular contractions, non-sustained SVT, and non-sustained ventricular tachycardia in ambulatory adults. These findings are relevant to short-term arrhythmia variability but do not establish sleep disturbance as a cause of sustained or recurrent SVT. ^[58]B2b

Metabolic treatment should not automatically be considered a risk factor. A 2025 systematic review and meta-analysis of randomized trials assessed arrhythmic, major cardiovascular, and microvascular outcomes among patients with type 2 diabetes treated with semaglutide; the supplied abstract describes the objective and methods but does not report an SVT-specific result. ^[43]A1a

Inflammation, critical illness, and perioperative risk

Psoriatic arthritis has been investigated as an inflammatory context for arrhythmia. A prospective cohort followed patients from 1994 to 2024 and assessed atrial tachyarrhythmia, defined to include atrial fibrillation and SVT, as well as ventricular tachyarrhythmia and bradycardia requiring pacing. Cox models examined disease-activity measures and age at arrhythmia occurrence; the supplied abstract does not provide the SVT-specific incidence or adjusted hazard estimates. ^[149]

Perioperative stress is an important setting for new-onset supraventricular arrhythmia. In adults undergoing single-port thoracoscopic lung-cancer surgery, a randomized trial defined postoperative SVT during the first 24 hours to include atrial flutter, atrial fibrillation, atrial tachycardia, and atrioventricular junctional tachycardia. ^[47]A1b In congenital-heart surgery, postoperative ectopic atrial tachycardia was diagnosed within 45 days of surgery, with a median diagnosis at 7 days; recurrence during the initial hospitalization occurred in approximately one-third of affected patients and often required intensified or additional antiarrhythmic treatment. ^[156]C Postoperative JET is described as frequent and potentially hemodynamically consequential after congenital-heart surgery, particularly in pediatric patients. ^[23]A1a

Critical illness and intensive-care treatment may further alter risk. A multicenter cohort of mechanically ventilated adults evaluated clinically significant SVT in relation to intravenous dexmedetomidine exposure, whose sympatholytic and vagotonic effects may influence atrioventricular-nodal conduction. ^[152]C A separate multicenter ICU study evaluated protocolized magnesium supplementation, triggered at serum magnesium ≤0.95 mmol/L (2.31 mg/dL), in relation to atrial fibrillation/flutter and secondary tachyarrhythmia outcomes that included SVT. ^[84]B2b These observational studies identify clinically relevant exposures and settings but do not by themselves prove that either dexmedetomidine or magnesium status causes SVT.

Structural, genetic, and congenital substrates

Underlying cardiac or syndromic disease may provide an arrhythmic substrate. Loeys–Dietz syndrome, a rare connective-tissue disorder with vascular, skeletal, and cutaneous abnormalities, has been evaluated for cardiac-arrhythmia prevalence, etiology, timing relative to cardiac surgery, and procedural complications. ^[155] Fetal atrial septal aneurysm has also been studied in fetuses with structurally normal hearts; the investigation assessed the presence and type of arrhythmia and ventricular hemodynamics. ^[151]C These reports support consideration of structural, developmental, and inherited conditions during risk assessment, but the supplied abstracts do not quantify their specific contribution to SVT.

Accessory pathways are an important substrate for pediatric SVT and pre-excitation. A study of 232 children with acutely successful radiofrequency accessory-pathway ablation assessed recurrence during a post-ablation waiting period, 24-hour Holter monitoring, and subsequent follow-up. ^[99]B3b Socioeconomic context can affect the observed epidemiology of pediatric SVT care: US studies examined insurance status, admission or transfer after emergency SVT encounters, and neighborhood-based Childhood Opportunity Index in relation to referral for electrophysiology study and ablation. ^[153][154] These findings concern access, utilization, and management disparities rather than biological susceptibility.

Practical summary

Risk assessment should therefore consider age, pregnancy, symptoms and monitoring intensity, cannabis exposure, sleep disturbance, inflammatory disease, critical illness, recent thoracic or congenital-heart surgery, electrolyte status, medications such as dexmedetomidine, accessory pathways, structural heart disease, and inherited syndromes. The strength of evidence varies substantially, and several cited studies address broader atrial or supraventricular arrhythmia categories rather than strictly defined SVT. ^{[44]B2a[58]B2b[149][152]C[156]C[155]}

Mechanistic substrate of supraventricular tachycardia

Supraventricular tachycardia (SVT) comprises tachyarrhythmias arising above the His bundle and includes re-entrant and focal atrial mechanisms. The supplied contemporary evidence primarily examines how autonomic modulation, atrioventricular (AV)-nodal conduction, abnormal automaticity, and targeted tissue injury influence SVT initiation or termination rather than redefining the electrophysiological taxonomy. ^{[54]A1a[22]A1a}

For regular paroxysmal SVT, termination by vagal maneuvers is consistent with a mechanism that depends on AV-nodal conduction or AV-nodal participation in the re-entry circuit. Standard Valsalva, modified Valsalva, carotid-sinus massage, and head-down deep breathing were compared in a 2025 network meta-analysis, which evaluated conversion after one attempt, after multiple attempts, and by the end of follow-up; the analysis also explored modification by age and sex. ^[54]A1a Randomized pediatric and orthopedic-patient studies similarly tested modified Valsalva against standard Valsalva, reporting greater sinus-rhythm conversion with the modified approach and no serious excess complications in the orthopedic cohort. ^{[57]A1b[138]A1b} A prehospital cohort and a stepped-wedge ambulance trial further evaluated Valsalva-based treatment in real-world care, including whether device availability reduced hospital conveyance. ^{[28]B3b[55]A1b}

Device-assisted Valsalva is intended to improve the pressure stimulus by helping patients achieve and maintain a target intrathoracic pressure; a randomized clinical trial evaluated this approach against standard Valsalva in patients undergoing electrophysiological study. ^[10]A1b These investigations support the concept that the physiological intensity, duration, and reproducibility of the maneuver can modify vagal treatment response, while the available abstracts do not establish a single universally superior technique across all patient groups. ^{[10]A1b[54]A1a[55]A1b}

Pharmacological modulation of conduction and automaticity

Adenosine remains the principal pharmacological treatment studied for vagal-refractory PSVT. Its clinical use is mechanistically consistent with transient suppression of AV-nodal conduction, although individual response is heterogeneous. A retrospective emergency-department study specifically examined demographic, clinical, electrocardiographic, and laboratory predictors of adenosine success, indicating that conversion cannot be assumed to be uniform among patients. ^[64]B3b A separate study evaluated predictors of the post-conversion sinus pause, identifying body mass index and symptom duration as candidate determinants of pause duration; transient pauses are therefore a clinically relevant consequence of abrupt nodal and sinus-node effects rather than a uniform response. ^[159]

Etripamil is an intranasal, fast-acting calcium-channel blocker developed for self-administered conversion of recurrent PSVT after an unsuccessful vagal maneuver. The NODE-303 study used ECG monitoring, an initial 70-mg dose, and an optional repeat 70-mg dose when symptoms persisted; the study specifically evaluated unsupervised use without a pre-treatment test dose. ^[25]B2b A post hoc analysis found that episodes initially presumed to be PSVT but subsequently identified as atrial fibrillation were also assessed for ventricular-rate slowing after intranasal etripamil, extending the drug’s observed electrophysiological effect beyond the original PSVT population. ^[24]B2b

Ivabradine represents a different mechanistic strategy because it inhibits the cardiac pacemaker current and is being investigated off-label for postoperative junctional ectopic tachycardia (JET), particularly after congenital-heart surgery. A systematic review and single-arm meta-analysis assessed conversion, time to conversion, recurrence, concomitant antiarrhythmic use, bradycardia, hypotension, QT prolongation, AV block, and mortality in children with postoperative JET. ^[23]A1a These data concern automatic or junctional tachycardia rather than typical AV-node-dependent re-entry and should not be generalized to all adult SVT. ^[23]A1a

Autonomic, inflammatory, and postoperative contributors

Autonomic imbalance may influence susceptibility to atrial arrhythmias. A large-population systematic review and meta-analysis reported that delta-9-tetrahydrocannabinol causes sympathetic stimulation and endothelial dysfunction and evaluated its association with atrial fibrillation, flutter, atrial tachycardia, and SVT. ^[44]B2a Ambulatory data also examined whether sleep duration, sleep disturbance, and self-rated sleep quality predicted next-day premature atrial contractions, premature ventricular contractions, nonsustained SVT, and nonsustained ventricular tachycardia. ^[58]B2b These studies support potentially modifiable autonomic or physiological influences but do not prove a specific causal pathway for recurrent PSVT. ^{[44]B2a[58]B2b}

Postoperative atrial and junctional tachycardias may reflect surgical substrate, acute myocardial stress, and altered conduction tissue. In a congenital-heart-surgery cohort, ectopic atrial tachycardia occurred within 45 days of surgery, commonly during the early postoperative period; recurrence during hospitalization often required escalation or addition of medication. ^[156]C Catheter ablation produces controlled myocardial injury and transient endothelial dysfunction, and a retrospective study evaluated post-ablation changes in the systemic immune-inflammation index across arrhythmia types. ^[157] In children undergoing SVT ablation, ventilation strategy was studied in relation to catheter-tissue interaction, lesion characteristics, and procedural metrics, linking procedural mechanics with lesion formation. ^[158]

Ablation as mechanism-directed therapy

Radiofrequency ablation treats the arrhythmogenic substrate by creating focal lesions, whereas pulsed-field ablation uses irreversible electroporation and is designed to limit collateral injury to adjacent structures. A systematic review of pulsed-field ablation in AVNRT, AVRT, and atrial tachycardia evaluated procedural success, complications, and recurrence, but the evidence base included only 10 studies, including case reports, and remains limited. ^[22]A1a In patients with vagal bradycardia and PSVT or frequent premature ventricular contractions, conventional ablation was combined in a randomized study with modification of the superior vena cava–aorta ganglionated plexus; this approach directly tested whether autonomic ganglion modification could alter heart rate and prognosis. ^[26]A1b

Evidence from syncope in pacemaker patients with bifascicular block showed that baseline clinical variables did not reliably predict recurrent syncope despite pacing, emphasizing that autonomic or non-bradycardic mechanisms may coexist with conduction disease. ^[56]B2b A long-term cohort after pulmonary-valve-stenosis repair supplied no direct mechanistic evidence for SVT. ^[83]B2b

Symptom pattern

Supraventricular tachycardia (SVT) may present with abrupt palpitations, dyspnea, anxiety or panic-like symptoms, and nausea. A 2026 emergency-department study specifically examined whether women with electrocardiographically confirmed SVT were more likely than men to report symptoms extending beyond palpitations, including anxiety, panic, and nausea; the available abstract does not provide the study’s numerical results. ^[150] In pregnancy, SVT has been described as causing palpitations and dyspnea and, when severe, maternal hemodynamic instability with potential fetal consequences. ^[89]C4

Symptoms may be intermittent because paroxysmal SVT is episodic. In a tertiary-center cohort of 427 adults with chart-confirmed paroxysmal SVT, investigators evaluated symptom presentation together with demographic factors, comorbidities, sex, and responses to pharmacological and non-pharmacological treatment; detailed symptom frequencies were not provided in the available abstract. ^[161]C Episodes initially perceived as paroxysmal SVT may occasionally represent another atrial tachyarrhythmia: in the NODE-303 study, adults with previously documented PSVT self-treated presumed episodes using an ECG monitor and vagal maneuver, and some episodes were subsequently identified as atrial fibrillation. ^[24]B2b

Electrocardiographic and temporal features

SVT includes more than sustained symptomatic episodes. Ambulatory monitoring studies distinguish premature atrial contractions, premature ventricular contractions, non-sustained SVT, and non-sustained ventricular tachycardia; one ambulatory-adult analysis evaluated whether sleep duration, sleep disturbance, or self-rated sleep quality predicted next-day arrhythmia frequency. ^[58]B2b In patients undergoing atrial-fibrillation ablation, SVT burden on 7–14-day ambulatory ECG monitoring was assessed as a predictor of recurrent atrial fibrillation, using episode count, average episodes per day, and the percentage of monitored days containing SVT. ^[167]

Vagal physiology may coexist with tachyarrhythmia. A randomized study enrolled 110 patients with premature ventricular contractions or PSVT and vagal bradycardia, comparing conventional arrhythmia ablation alone with additional modification of the right atrial superior vena cava–aorta ganglionated plexus. ^[26]A1b This combination is clinically relevant because patients may present with both episodic tachycardia and resting or reflex bradycardia rather than with tachycardia alone. ^[26]A1b

Age-specific presentation

Neonatal SVT can occur very early in life. In a multicenter 10-year experience involving 32 neonates, the median age at onset was 14 days, and 59% were male. The documented mechanisms were atrioventricular reentrant tachycardia in 72%, atrioventricular nodal reentrant tachycardia in 9%, permanent junctional reciprocating tachycardia in 9%, and focal atrial tachycardia in 9%. ^[162] Median ejection fraction was 60% overall but 39% among the subgroup identified in the abstract as having reduced ventricular function, indicating that neonatal SVT may be associated with ventricular dysfunction. ^[162]

Postoperative junctional ectopic tachycardia is a clinically important pediatric presentation after congenital-heart surgery. A systematic review and single-arm meta-analysis evaluated children <18 years treated with oral or nasogastric ivabradine, examining conversion to sinus rhythm, time to conversion, recurrence, concomitant antiarrhythmic-drug use, bradycardia, hypotension, QT prolongation, atrioventricular block, and mortality; numerical pooled outcomes were not included in the supplied abstract. ^[23]A1a Pediatric SVT may also progress to tachycardia-induced cardiomyopathy; a 12-child retrospective study evaluated clinical characteristics in relation to arrhythmia type and duration, together with echocardiographic findings and outcomes after radiofrequency ablation. ^[165]C

Associated disease and uncommon contexts

Arrhythmias, including atrial tachyarrhythmias defined as atrial fibrillation or SVT, have been prospectively evaluated in patients with psoriatic arthritis followed at 6–12-month intervals from 1994 to 2024. ^[149] Congenital or structural abnormalities may provide an arrhythmic context: a systematic review of 44 right-atrial-appendage aneurysm cases found male predominance (68.2%), presentation most often in the third decade, and palpitations and dyspnea as the most frequently reported symptoms, occurring in 27.3% and 18.2%, respectively. ^[27]C4

SVT-like presentations can also occur in systemic or neonatal inflammatory illness. In a single-center series of 15 neonates with multisystem inflammatory syndrome associated with prenatal maternal SARS-CoV-2, all neonates had cardiac involvement, including SVT and persistent sinus abnormalities. ^[166] Pediatric scorpion and snake envenomation is another setting in which serious systemic complications may develop; a Turkish retrospective study described clinical features, management, and outcomes in children presenting after these exposures, although the supplied abstract does not specify the frequency or phenotype of SVT. ^[160]

Clinical course and immediate risk

The clinical impact ranges from brief, self-limited palpitations to hemodynamic compromise or ventricular dysfunction, depending on age, substrate, episode duration, and associated disease. ^{[89]C4[162][165]C} In emergency-care cohorts, adenosine was used for successful cardioversion of SVT, but transient post-conversion sinus pauses were sufficiently variable to prompt evaluation of age, body-mass index, and symptom duration as predictors. ^[159] Accordingly, presentation should document onset and termination pattern, symptom severity, duration, recurrence, associated bradycardia, and evidence of circulatory or ventricular compromise. ^{[23]A1a[26]A1b[159][162]}

Clinical recognition and initial confirmation

Supraventricular tachycardia (SVT) should be evaluated as a rhythm diagnosis rather than inferred from palpitations alone. In the emergency-department evidence base, adults with hemodynamically stable SVT were eligible only when the rhythm was confirmed by a 12-lead electrocardiogram (ECG). ^[168] The initial assessment should therefore document symptoms, hemodynamic status, onset and termination pattern, and obtain a 12-lead ECG during tachycardia whenever possible. ^[168] A rhythm that appears to be paroxysmal SVT may occasionally be atrial fibrillation (AF): in a phase 3 study of patients with prior documented PSVT who self-treated presumed PSVT episodes, some episodes were subsequently identified as AF. ^[24]B2b When the arrhythmia is intermittent and not captured in the clinical setting, an ambulatory ECG monitor can help correlate symptoms with the rhythm; in the NODE-303 protocol, patients applied an ECG monitor before self-administering treatment. ^[24]B2b

The ECG record should be retained for specialist review and should establish whether the episode is regular or irregular, sustained or nonsustained, and whether a narrow- or wide-complex tachycardia is present; the supplied studies specifically support ECG confirmation of stable SVT but do not provide validated diagnostic ECG thresholds for these subdivisions. ^[168] Non-sustained SVT may be detected incidentally during ambulatory monitoring. The CRAVE secondary analysis evaluated premature atrial contractions, premature ventricular contractions, non-sustained SVT, and non-sustained ventricular tachycardia as clinically relevant ambulatory arrhythmias. ^[58]B2b

Hemodynamic and emergency assessment

Before pursuing rhythm classification, determine whether the patient is stable and assess for consequences such as hypotension, altered mental status, dyspnoea, chest discomfort, or heart failure. The available emergency study specifically enrolled adults aged ≥18 years with hemodynamically stable, ECG-confirmed SVT, so its findings should not be extrapolated to unstable patients or children. ^[168] Vagal manoeuvre and adenosine studies are treatment studies, not substitutes for diagnostic ECG documentation: the modified-Valsalva trial enrolled adults with stable PSVT, while the adenosine study required stable SVT confirmed by 12-lead ECG. ^[169][168]

Pediatric, neonatal, and fetal workup

Age and developmental context materially affect the differential diagnosis and investigation. In a multicenter neonatal series, the median age at SVT onset was 14 days; mechanisms included atrioventricular reentrant tachycardia (AVRT) in 72%, atrioventricular nodal reentrant tachycardia (AVNRT) in 9%, permanent junctional reciprocating tachycardia in 9%, and focal atrial tachycardia in 9%. ^[162] Neonatal evaluation should therefore include rhythm documentation, echocardiography, assessment of ventricular function, and review of biomarkers and therapies, all of which were collected in that cohort. ^[162] Reduced ventricular function may indicate tachycardia-induced cardiomyopathy; among neonates in the same study, median ejection fraction was 60% overall and 39% in those with impairment. ^[162]

In children with suspected tachycardia-induced cardiomyopathy, the diagnostic workup should include serial ECGs and echocardiographic assessment of ventricular function, because pediatric outcome analyses collected ECG, echocardiographic, treatment, and follow-up data and linked prognosis to arrhythmia type and duration. ^[165]C

For fetal tachyarrhythmia, diagnosis requires fetal echocardiographic confirmation. A consistent-protocol fetal cohort included sustained tachyarrhythmia confirmed by echocardiography and excluded fetuses with significant congenital heart disease. ^[170]C Fetal atrial septal aneurysm is defined in the cited echocardiographic study as redundant atrial septum primum bowing >50% into the left atrium; isolated cases were evaluated for associated arrhythmia and ventricular hemodynamics. ^[151]C

Structural and anatomic evaluation

Transthoracic echocardiography is appropriate when structural heart disease, ventricular dysfunction, congenital disease, or an unusual age of presentation is suspected; neonatal and fetal studies demonstrate its use for rhythm-associated ventricular and structural assessment. ^{[162][170]C[151]C} Rare structural substrates should be considered when clinical findings are atypical. Right atrial appendage aneurysm is an uncommon condition reported across 44 published cases, with palpitations and dyspnoea among the common presentations; reported evaluations included ECG, chest radiography, echocardiography, CT, and cardiac MRI. ^[27]C4

Cardiac CT may provide additional anatomic information in selected patients being evaluated for ablation. In a study of patients with successfully ablated AVNRT or AVRT, CT angiography was used to measure coronary sinus ostium dimensions at the right-atrial junction. ^[163] This is an adjunctive anatomic investigation rather than a stand-alone diagnostic test for SVT. Three-dimensional electroanatomic mapping and intracardiac echocardiography are principally procedural tools used to guide ablation and reduce radiation exposure, not routine first-line diagnostic tests. ^{[63]A1a[164]C}

Electrophysiology referral and procedural planning

Patients with documented recurrent or diagnostically uncertain SVT may require an electrophysiology study to define the mechanism and guide ablation. The available procedural studies describe conventional electrophysiological examination for PSVT and compare conventional fluoroscopy with zero- or minimal-fluoroscopy approaches supported mainly by electroanatomic mapping, with intracardiac echocardiography used selectively when clinically indicated. ^{[26]A1b[63]A1a} In AVNRT, three-dimensional mapping-guided ablation has been evaluated as an alternative to conventional fluoroscopic guidance, with the objective of reducing radiation while maintaining procedural efficacy. ^[164]C

Scope and principles

The available evidence does not establish a single, universally validated severity-staging system for supraventricular tachycardia (SVT); instead, studies have classified risk by hemodynamic consequence, episode burden, recurrence, patient age, underlying cardiac disease, and clinical setting. ^{[72]B2b[156]C[176]C} Severity assessment should therefore begin with immediate clinical status, followed by characterization of tachycardia burden and identification of structural, congenital, postoperative, heart-failure, pregnancy-related, or neonatal risk modifiers. ^{[71]B2b[72]B2b[174][176]C}

Practical severity stages

Stage 1—low immediate risk or limited burden. This category includes brief, self-terminating or infrequent SVT without documented hemodynamic compromise, although the supplied references do not define a universal duration or rate threshold for this group. ^[72]B2b[172] In patients with mild heart failure enrolled in MADIT-CRT, new SVT occurred in 41 patients, representing 3% of the analyzed cohort, during a mean follow-up of 3.4 ± 1.1 years. ^[72]B2b The study categorized SVT burden as low (<10 episodes), intermediate (≥10 but <20 episodes), or high (≥20 episodes) per patient. ^[72]B2b These episode-count thresholds are useful for describing recurrence burden, but they should not be interpreted as a validated measure of acute danger in all populations. ^[72]B2b

Stage 2—clinically significant or recurrent SVT. Recurrent episodes, increasing episode count, symptoms, emergency-department presentation, or SVT occurring with comorbidity should prompt assessment for precipitating disease and cardiac substrate. ^[72]B2b[172] A large retrospective emergency-department analysis specifically evaluated 1-year all-cause death or thromboembolism after SVT admission and compared patients coded as SVT, atrial fibrillation, atrial flutter, and controls; patients taking oral anticoagulation were excluded. ^[172] Because the supplied evidence does not provide the study’s numerical outcome estimates, the analysis supports outcome-oriented risk assessment but does not establish a numerical 1-year risk threshold from this reference alone. ^[172]

In heart failure with reduced ejection fraction, nocturnal arrhythmia risk should be interpreted alongside sleep-apnea phenotype and severity. ^[71]B2b The ADVENT-HF ancillary study compared clinically important nocturnal atrial and ventricular arrhythmias among patients with obstructive sleep apnea, central sleep apnea, and no-to-mild sleep apnea, and examined whether apnea severity was associated with atrial or ventricular nocturnal arrhythmias. ^[71]B2b This evidence supports considering sleep-disordered breathing as a risk modifier in HFrEF, but it does not justify assigning an SVT stage solely from apnea severity. ^[71]B2b

Stage 3—high-risk SVT. SVT should be considered high risk when it is sustained or associated with hypotension, heart-failure deterioration, ischemia, syncope, altered mental status, or other evidence of inadequate perfusion; however, the supplied references do not provide a validated SVT-specific threshold for any of these findings. ^[72]B2b[172] Age and substrate are important: among neonates and infants younger than 1 year with symptomatic, non-postoperative SVT, pharmacologic therapy was successful in 151 of 157 patients (96%), 1% required catheter ablation, and 5 patients (3%) died; one death was linked to hemodynamic causes after effective arrhythmia control. ^[176]C Serious complications after acute medical therapy were also reported in this population. ^[176]C

Population-specific risk modifiers

Pregnancy in adults with congenital heart disease is a higher-surveillance setting. ^[174] In a cohort of 172 pregnancies in 137 patients, clinically significant arrhythmia occurred in 25 pregnancies (15%); 64% of events occurred during the second trimester, and sustained SVT was the most common rhythm. ^[174] Preconception ablation and congenital-heart-disease characteristics were evaluated as potential predictors, but the supplied abstract does not provide the complete score or effect estimates. ^[174]

Postoperative ectopic atrial tachycardia (EAT) after congenital-heart surgery also warrants recurrence-focused stratification. ^[156]C Among 167 patients diagnosed within 45 days of surgery, 32% had recurrence during the initial hospitalization requiring escalation of dosing or initiation of new medication. ^[156]C The cohort was predominantly very young, with a median age of 1.7 months, and EAT occurred at a median of 7 days after surgery. ^[156]C Follow-up recurrence was assessed, but the supplied abstract excerpt is truncated and does not provide a complete interpretable estimate. ^[156]C

Fetal SVT is potentially morbid when sustained. ^[181]C In a 30-year single-institution cohort, sustained fetal SVT was defined as present during >50% of the diagnostic echocardiogram; 65 fetuses were diagnosed at a median gestational age of 30 weeks, and atrioventricular re-entrant tachycardia and atrial flutter were the most common diagnoses. ^[181]C The report described low mortality, while emphasizing that untreated sustained fetal SVT is associated with significant morbidity and mortality. ^[181]C

Procedural and diagnostic context

Risk stratification should distinguish arrhythmia severity from procedural risk. ^{[22]A1a[99]B3b[180]C} A systematic review of pulsed-field ablation for SVT included 10 studies—three case reports and seven other studies—covering atrioventricular nodal re-entry tachycardia, atrioventricular re-entry tachycardia, and atrial tachycardia; it evaluated procedural success, complications, and recurrence, but the supplied excerpt does not provide pooled numerical estimates. ^[22]A1a In a pediatric radiofrequency accessory-pathway study, 232 patients with acute procedural success underwent a 30-minute post-ablation waiting-period test and 24-hour Holter monitoring; recurrence during the waiting period and subsequent follow-up were assessed. ^[99]B3b In a mixed ablation cohort, emergent computed tomography for suspected femoral vascular complications occurred in 8 patients (2.6%). ^[180]C

Other cited studies provide contextual rather than SVT-specific risk information. ^{[26]A1b[73]B3b[74]B2b[157][175][177][178][179][182]} A randomized study of 110 patients with PSVT or frequent premature ventricular contractions and vagal bradycardia compared conventional ablation alone with additional superior vena cava–aorta ganglionated-plexus modification, with 55 patients per group. ^[26]A1b Studies of idiopathic ventricular fibrillation, early-repolarization syndrome, sudden cardiac death in adult congenital heart disease, systemic immune-inflammation after ablation, multiple-myeloma arrhythmias, emergency-department monitoring, medication exposure, polymyositis-dermatomyositis, and neonatal arrhythmias should not be used to assign SVT severity without arrhythmia-specific clinical correlation. ^{[73]B3b[74]B2b[157][175][177][178][179][182]}

Immediate assessment and triage

Patients presenting with a suspected supraventricular tachycardia (SVT) should undergo prompt clinical assessment and 12-lead electrocardiography, with particular attention to haemodynamic status, rhythm regularity, QRS duration, symptoms, and potentially reversible precipitants. In the prospective emergency-department study of adults, inclusion required haemodynamically stable SVT confirmed by 12-lead ECG, illustrating the importance of distinguishing stable from unstable presentations before selecting pharmacological treatment ^[168]. Retrospective emergency and prehospital studies show that SVT may be managed across different settings, but documentation and diagnostic confirmation are variable outside hospital; therefore, an ECG-confirmed diagnosis remains preferable whenever feasible ^{[28]B3b[82]B3b[161]C}.

Haemodynamic instability, severe ongoing symptoms, altered mental status, shock, acute heart failure, or myocardial ischaemia should prompt urgent synchronized electrical cardioversion according to local advanced-life-support protocols. The supplied studies do not directly compare cardioversion strategies or define an instability threshold, but cardioversion was included among the non-pharmacological treatments evaluated in a tertiary-centre PSVT cohort ^[161]C.

Stable regular SVT: vagal manoeuvres

For haemodynamically stable, regular SVT, vagal manoeuvres are an appropriate initial intervention. A 2026 prehospital cohort specifically evaluated Valsalva manoeuvres in patients with suspected tachyarrhythmia and confirmed SVT, reflecting their role as first-line treatment in real-world emergency medical services ^[28]B3b. A failed manoeuvre should not delay escalation to drug therapy when the rhythm persists or symptoms worsen ^[28]B3b.

The evidence supplied does not establish that one vagal technique is superior to another, nor does it provide a validated patient-selection algorithm. Vagal manoeuvres should therefore be attempted when clinically appropriate, while maintaining monitoring and readiness for adenosine or cardioversion ^[28]B3b[168].

Adenosine after unsuccessful vagal manoeuvres

Intravenous adenosine is the principal acute drug studied in the supplied evidence for stable SVT. In a prospective cohort of 155 adults whose SVT was refractory to vagal manoeuvres, all patients initially received 6 mg adenosine; first-dose conversion to sinus rhythm occurred in 58.1% of patients ^[86]B2b. This study examined the relationship between body weight and first-dose success and used receiver-operating-characteristic analysis to explore a weight-adjusted threshold, but the supplied abstract does not report the final optimal dose or establish a replacement for the standard fixed-dose approach ^[86]B2b.

A separate prospective observational emergency-department study compared an initial 12-mg dose with 6 mg in haemodynamically stable adults with ECG-confirmed SVT. The primary outcome was successful conversion after the first dose, with secondary assessment of adenosine-related adverse effects; propensity-score matching was used to reduce selection bias ^[168]. Because this was observational rather than randomized evidence, the choice of an initial 12-mg dose should be individualized and should not automatically replace the conventional initial 6-mg strategy ^[168].

A practical approach supported by these studies is to use monitored intravenous adenosine after unsuccessful vagal manoeuvres, beginning with 6 mg where this is consistent with local protocol, and to consider patient size, prior response, and local policy when deciding whether an initial 12-mg dose is appropriate ^[86]B2b[168]. Continuous ECG monitoring is essential because adenosine can produce transient rhythm effects and because failure to terminate the rhythm may indicate an incorrect diagnosis or a non-AV-nodal mechanism; the supplied studies assessed conversion and adverse effects but do not provide a complete safety protocol ^[168].

Special clinical contexts

Postoperative junctional ectopic tachycardia (JET) in children after congenital-heart surgery is a distinct postoperative tachyarrhythmia and should not be managed as routine adult paroxysmal SVT. A systematic review and single-arm meta-analysis evaluated oral or nasogastric ivabradine in children younger than 18 years with postoperative JET, examining conversion, time to conversion, recurrence, concomitant antiarrhythmic use, bradycardia, hypotension, QT prolongation, atrioventricular block, and mortality ^[23]A1a. Ivabradine was used off-label, and the supplied evidence does not provide enough outcome detail to recommend it as universal first-line therapy; specialist paediatric and postoperative cardiac management is required ^[23]A1a.

In critically ill mechanically ventilated adults, dexmedetomidine exposure was investigated in a multicentre retrospective cohort because its sympatholytic and vagotonic effects may alter atrioventricular-nodal conduction and clinically significant SVT risk ^[152]C. This observational association should not be interpreted as evidence that dexmedetomidine treats acute SVT or as a basis for abrupt discontinuation; medication review should instead form part of individualized critical-care assessment ^[152]C.

Pregnancy requires individualized risk assessment because maternal cardiac arrhythmias have been studied in relation to pre-eclampsia, stillbirth, preterm delivery, and small-for-gestational-age birth outcomes ^[45]B2a. The supplied meta-analysis addresses associations between arrhythmias and pregnancy outcomes rather than comparative acute SVT treatments, so it does not support a pregnancy-specific drug hierarchy ^[45]B2a.

Definitive treatment after stabilization

Recurrent or symptomatic SVT should be referred for electrophysiological evaluation and consideration of catheter ablation. Catheter ablation is described as the treatment of choice for SVT in the updated systematic review comparing zero- or minimal-fluoroscopy with conventional fluoroscopy ^[63]A1a. Zero- or minimal-fluoroscopy approaches, generally enabled by electroanatomic mapping with selective adjunctive intracardiac echocardiography, are intended to reduce radiation exposure while preserving procedural efficacy and safety ^[63]A1a.

For AVNRT in children and young people, zero-fluoroscopy radiofrequency slow-pathway modification has been evaluated in patients aged ≤21 years, with three-dimensional electroanatomic mapping used to reduce radiation exposure ^[187]. A randomized paediatric trial also compared anatomical mapping with voltage, activation-time, and propagation-guided mapping for AVNRT, although the supplied abstract does not report comparative outcome data ^[185]. Contact-force sensing has been tested in a randomized trial of AVNRT and AVRT, with radiofrequency application number as the primary endpoint and procedural, safety, efficacy, and long-term outcomes as secondary endpoints ^[183]. PFA has likewise been compared with RFA in a prospective multicentre propensity-matched study of 621 patients with PSVT over 12 months, including separate AVNRT and AVRT analyses ^[184]C. These technologies concern definitive ablation rather than initial emergency termination and should not delay appropriate acute stabilization ^{[63]A1a[183][184]C[185]}.

Scope and treatment selection

Long-term management should be individualized according to the documented supraventricular tachycardia (SVT) mechanism, episode frequency and duration, symptom burden, hemodynamic effect, ventricular function, comorbidity, patient preference, and procedural risk. The supplied 2026 literature adds evidence mainly for acute termination, catheter ablation, selected bradycardic phenotypes, and special populations; it does not replace mechanism-specific guideline recommendations for chronic therapy. ^{[10]A1b[23]A1a[26]A1b[184]C}

Catheter ablation

For recurrent symptomatic paroxysmal SVT, referral to an electrophysiology service for consideration of catheter ablation remains the most definitive long-term strategy when the arrhythmia mechanism is suitable. The new evidence is most directly relevant to procedural technique rather than to the indication itself. A multicenter prospective study enrolled 621 patients with paroxysmal SVT treated with pulsed-field ablation (PFA) or radiofrequency ablation (RFA), with propensity matching performed separately for atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia and follow-up planned to 12 months; because this was a propensity-score comparison rather than randomization, its findings should be interpreted as comparative observational evidence. ^[184]C

Pediatric procedural practice is also evolving. In a prospective observational study of 133 patients younger than 18 years undergoing radiofrequency ablation for SVT, ventilation strategies included high-frequency low-tidal-volume ventilation, standard ventilation, and controlled apnea; the study evaluated catheter–tissue interaction, lesion characteristics, and procedural metrics, but ventilation strategy was not randomized. ^[158] A separate retrospective analysis of 642 adults undergoing ablation across arrhythmia types examined changes in the systemic immune-inflammation index before and 1 week after ablation, supporting awareness of transient post-procedural inflammatory responses but not establishing a long-term treatment endpoint. ^[157]

Patients with SVT or frequent premature ventricular contractions combined with vagally mediated bradycardia may require a specialized strategy. In a randomized study of 110 patients, all participants underwent conventional electrophysiologic evaluation and ablation of the tachyarrhythmia; the intervention group then received superior vena cava–aorta ganglionated-plexus modification as cardioneuroablation, whereas controls did not. This approach should be considered investigational or highly selective until broader evidence clarifies durability, risks, and patient selection. ^[26]A1b

Pharmacologic maintenance and special populations

The supplied references do not provide a randomized chronic drug-comparison trial for routine adult SVT maintenance. Ivabradine is being evaluated primarily as an off-label treatment for postoperative junctional ectopic tachycardia (JET), not as standard long-term therapy for typical adult AVNRT or AVRT. A systematic review and single-arm meta-analysis included five studies of children younger than 18 years with postoperative JET treated with oral or nasogastric ivabradine and assessed conversion, time to conversion, recurrence, concomitant antiarrhythmic use, bradycardia, hypotension, QT prolongation, atrioventricular block, and mortality; single-arm evidence cannot establish comparative efficacy. ^[23]A1a

Neonatal and postoperative arrhythmias require specialist management rather than direct extrapolation from adult SVT pathways. A multicenter retrospective study of 32 neonates found AVRT in 72%, AVNRT in 9%, permanent junctional reciprocating tachycardia in 9%, and focal atrial tachycardia in 9%; median overall ejection fraction was 60%, but 39% among those with ventricular dysfunction. ^[162] Another specialized-center neonatal series reviewed arrhythmia type, treatment, recurrence, morbidity, and mortality, emphasizing the heterogeneity of neonatal disease and the need for individualized follow-up. ^[182] A case report described dual tachycardia in a premature infant consisting of persistent atrial tachycardia with brief ventricular tachycardia, illustrating why atypical neonatal rhythms require definitive rhythm characterization. ^[91]C4

Patient-directed and acute-response planning

Although vagal maneuvers are acute rather than maintenance therapy, education may reduce emergency utilization and form part of a long-term self-management plan for appropriately selected patients with stable, previously characterized SVT. A randomized clinical trial evaluated a handheld device designed to help patients achieve and maintain target intrathoracic pressure during Valsalva; the study was undertaken because standard Valsalva success is suboptimal, but the available abstract does not provide the comparative outcome data. ^[10]A1b A prehospital retrospective cohort from Poland evaluated Valsalva use among 93,847 EMS interventions and identified 235 cases coded as unspecified tachycardia, assessing ECG findings, maneuver performance, termination, and transport decisions; coding and retrospective design limit inference about confirmed SVT effectiveness. ^[28]B3b

For stable emergency presentations, intravenous adenosine remains an acute treatment rather than chronic prophylaxis. A prospective observational study compared initial 6-mg versus 12-mg adenosine in adults with ECG-confirmed SVT after propensity matching, evaluating first-dose conversion and adverse effects. ^[168] Another emergency-department study examined predictors of adenosine-associated sinus-pause duration, focusing on age, body mass index, and symptom duration; clinicians should anticipate transient pauses after conversion, although this evidence does not define long-term therapy. ^[159]

Etripamil nasal spray is likewise an episodic self-administered intervention, not established maintenance treatment for SVT. In the NODE-303 post hoc analysis, adults with previously documented PSVT applied ECG monitoring, performed a vagal maneuver, and self-administered 70 mg, with an optional second 70-mg dose; the analysis concerned episodes later identified as atrial fibrillation and therefore should not be generalized to confirmed AVNRT or AVRT. ^[24]B2b

Comorbidity, follow-up, and safety

Metabolic risk-factor management should be incorporated into long-term cardiovascular care. In a UK Biobank cohort of 383,995 participants followed for a median of 13.0 years, both prediabetes and type 2 diabetes were associated with increased risks of arrhythmias, including SVT, with analyses using ADA and WHO/IEC criteria and Mendelian randomization. ^[87]B2b

Sedative exposure may be relevant in critically ill patients but should not be interpreted as outpatient SVT prevention. A time-dependent propensity-score study across 11 hospitals examined intravenous dexmedetomidine and clinically significant SVT in mechanically ventilated adults; its retrospective design supports medication-risk awareness rather than a treatment recommendation. ^[152]C Observational studies from Bahrain and a tertiary emergency department evaluated PSVT characteristics, treatment responses, cardioversion, follow-up, and sex-related symptom or management differences, supporting attention to diagnostic confirmation and equitable follow-up but not establishing chronic treatment efficacy. ^[161]C[150]

The remaining supplied evidence concerns pediatric envenomation, fetal tachyarrhythmia, and suspected acute coronary syndrome rather than long-term SVT therapy. Pediatric scorpion and snake-envenomation data address toxicologic complications, fetal tachyarrhythmia research examines protocolized antenatal care and socioeconomic factors, and coronary CT angiography research concerns suspected ACS outcomes; none should be used to select chronic SVT treatment. ^{[160][170]C[186]C}

Practical long-term pathway

Confirm the rhythm mechanism, document recurrence and burden, assess ventricular function and comorbidity, discuss ablation versus medication or episodic management, and arrange follow-up appropriate to age and substrate. Evidence for PFA, cardioneuroablation, ivabradine in postoperative JET, device-assisted Valsalva, and self-administered etripamil remains population- or context-specific and should not be extrapolated uncritically to routine adult SVT. ^{[10]A1b[23]A1a[24]B2b[26]A1b[184]C}

Long-term management of supraventricular tachycardia (SVT) often transitions from pharmacological suppression to definitive interventional strategies, primarily catheter ablation , which is recommended as first-line therapy to prevent recurrence ^[30]D5. While medications like beta-blockers and calcium channel blockers remain options, ablation offers high curative potential with single-procedure success rates ranging from 94.3% to 98.5% ^[30]D5.

Step 1: Electrophysiological Study and Risk Stratification

Invasive electrophysiological study (EPS) is indicated for symptomatic patients and high-risk asymptomatic individuals with pre-excitation. In patients with asymptomatic Wolff-Parkinson-White (WPW) pattern, the risk of sudden cardiac death (SCD) is estimated at 1.25 per 1000 person-years (95% CI, 0.57-2.19) ^[32]B2a.

• Asymptomatic Pre-excitation: Ablation reduces the 5-year incidence of arrhythmic events from 77% to 7% (RRR 0.08; 95% CI, 0.02-0.33; P<0.001) ^[1]A1a[2]A1a.
• Induction Indices: When tachycardia is non-sustained, the induction postpacing interval (iPPI) minus tachycardia cycle length (TCL) can differentiate mechanisms. A corrected iPPI-TCL ≤110 ms identifies orthodromic reciprocating tachycardia (ORT) with 90.2% sensitivity and 100% specificity ^[100]B3b.

Step 2: Catheter Ablation

Radiofrequency ablation ( RFA ) is the standard of care for most SVT subtypes, though cryoablation and pulsed field ablation (PFA) are emerging for anatomically challenging pathways ^[97]C4.

• AVNRT: Periprocedural success is highest for atrioventricular nodal reentrant tachycardia at 98.9% ^[42]B2b. Atypical fast-slow AVNRT incorporating a superior slow pathway near the His bundle can be successfully eliminated via RFA ^[16]C4.
• Atrial Flutter : Success rates are high, but these patients exhibit higher 1-year mortality (2.6%) and stroke rates compared to other SVT groups, necessitating long-term anticoagulation ^[42]B2b.
• Pediatric Populations: In children <15 kg and <5 years, acute success is approximately 94% ^[85]D5. Older age at the time of procedure is a significant independent predictor of long-term success ^[96]B3b.

Step 3: Device Programming and Management

In patients with implantable cardioverter-defibrillators (ICDs), SVT is a leading cause of inappropriate shocks, occurring in 11.5% of patients in the MADIT II cohort ^[38]B2b.

• Detection Enhancements: Dual-chamber ICDs reduce the odds of inappropriate SVT detection by nearly half (OR 0.53; 95% CI, 0.30-0.94; P=0.03) compared to single-chamber devices ^[3]A1b.
• Standardized Programming: Empiric programming (e.g., detection rates ≥182 bpm for 30 of 40 beats) reduces shocks from 17% to 9% (p < 0.01) ^[35]B2b.
• Subcutaneous ICD (S-ICD): Inappropriate shocks for SVT or atrial fibrillation occur in 8.1% of patients at 1 year ^[81]B2b.

Controversies and Guideline Disagreement

Pearl: Catheter ablation is the definitive therapy for SVT with success rates exceeding 94%, but clinicians must maintain a 30-minute post-ablation waiting period to reduce the risk of recurrence, particularly in manifest accessory pathways ^{[30]D5[99]B3b}.

Treatment framework

The supplied contemporary evidence describes treatment of supraventricular tachycardia (SVT) as progressing from bedside vagal stimulation toward more reproducible, device-assisted techniques, rapid pharmacological conversion, and increasingly individualized catheter-based therapy. In hemodynamically stable patients, the Valsalva maneuver remains the guideline-directed emergent treatment, although its effectiveness is limited by difficulty achieving and sustaining the required intrathoracic pressure. ^[10]A1b In children with paroxysmal SVT (PSVT), vagal maneuvers are likewise described as the initial-line intervention. ^[57]A1b

The evidence base also emphasizes that treatment selection depends on age, mobility, pregnancy, concomitant bradycardia, anatomy, and the clinical setting. Randomized trials have evaluated modified Valsalva techniques in children and in adults with limited lower-limb activity after orthopedic surgery, while newer studies have examined device-assisted Valsalva in electrophysiology laboratories and ambulance services. ^{[10]A1b[55]A1b[57]A1b[138]A1b}

Evolution of vagal maneuvers

Standard Valsalva has been adapted to improve venous return and vagal activation after straining. A randomized pediatric trial enrolled 90 children with PSVT and allocated them equally to conventional hospital care, standard Valsalva, or modified Valsalva treatment. ^[57]A1b The study specifically evaluated clinical outcomes and patient satisfaction, reflecting a shift from simply attempting termination to assessing usability and experience. ^[57]A1b In a randomized study of 60 postoperative orthopedic patients with limited lower-limb mobility, nurse-assisted modified Valsalva was compared with traditional Valsalva; the modified technique produced a significantly higher sinus-conversion rate without serious complications compared with the traditional approach. ^[138]A1b

Device assistance represents a further evolution intended to standardize maneuver performance. A single-center randomized clinical trial at Beijing Anzhen Hospital enrolled patients aged 16–80 years undergoing electrophysiological study between April 2022 and April 2023 and compared a handheld Valsalva-assist device with standard Valsalva. ^[10]A1b The device was designed to help patients achieve and maintain target intrathoracic pressures, directly addressing a principal limitation of unaided Valsalva. ^[10]A1b A pragmatic stepped-wedge cluster-randomized trial in United Kingdom ambulance services evaluated availability of a simple Valsalva device during usual care for adults treated for suspected SVT, using hospital conveyance as the principal service-level outcome. ^[55]A1b These trials extend modified Valsalva from a clinician-taught maneuver to a potentially reproducible out-of-hospital intervention, although the supplied abstracts do not provide the complete comparative outcome data. ^{[10]A1b[55]A1b}

Other vagal approaches remain relevant, particularly in children. A randomized trial of 120 hemodynamically stable children compared carotid sinus massage with an ice-bag maneuver administered by trained nurses; success was defined as restoration of sinus rhythm within 5 minutes. ^[193] In the carotid-massage group, 26 children (43.3%) returned to sinus rhythm; the supplied abstract does not report the complete result for the ice-bag group. ^[193] Because carotid sinus massage has recognized procedural and patient-selection considerations, the trial’s nurse-delivered design illustrates the continuing effort to make pediatric vagal treatment more systematic rather than establishing universal superiority. ^[193]

Pharmacological conversion

Adenosine remains the first-line pharmacological agent for vagal-refractory PSVT in emergency practice. ^[64]B3b Contemporary work has moved beyond the assumption of uniform response: a retrospective study examined demographic, clinical, electrocardiographic, and laboratory variables associated with adenosine success in adults with electrocardiographically confirmed PSVT treated between January 2023 and May 2025. ^[64]B3b The study’s focus on response heterogeneity supports a more individualized approach when adenosine fails, although the supplied abstract does not provide the final predictors or effect estimates. ^[64]B3b

Administration technique has also been studied as a practical treatment issue. A randomized crossover simulation involving 16 pharmacist–physician pairs compared single-syringe and double-syringe adenosine administration in a simulated pediatric emergency patient, assessing administration time, preparation time, errors, ease of use, and preference. ^[134]A1b The study was designed to determine whether syringe configuration could improve delivery reliability, but the supplied abstract does not include the complete comparative results. ^[134]A1b

Catheter ablation and specialized populations

Catheter ablation has become an important definitive treatment pathway for recurrent or difficult-to-manage SVT, with current evidence extending its application to complex anatomy and combined bradycardia–tachycardia syndromes. In patients with congenitally corrected transposition of the great arteries, a retrospective single-center cohort evaluated 29 of 112 patients (26%) who underwent ablation and stratified outcomes by anatomical repair, physiologic repair, or no prior surgery. ^[189]C Another electrophysiological study examined unusual coronary-sinus activation changes during ablation of left free-wall accessory pathways in 8 patients, demonstrating that activation patterns may change after initial ablation and can require reassessment. ^[191]C

A randomized study of 110 patients with PVCs or PSVT and vagal bradycardia compared conventional arrhythmia ablation alone with additional superior vena cava–aorta ganglionated plexus modification, a cardioneuroablation strategy intended to address vagally mediated bradycardia. ^[26]A1b Pregnancy has likewise prompted procedural innovation: a case report described successful three-dimensional intracardiac-ultrasound-guided radiofrequency ablation for pregnancy-associated SVT while avoiding radiation exposure. ^[89]C4 These reports support increasingly tailored ablation strategies, but the randomized and observational evidence remains specific to selected populations. ^{[26]A1b[89]C4[189]C}

Broader treatment-related considerations

The modern history of SVT treatment also includes improved rhythm documentation and post-treatment risk assessment. A randomized pediatric study compared a smartphone-based single-lead ECG recorder with a conventional event recorder for symptom–rhythm correlation in children with palpitations. ^[135]A1b Ambulatory SVT burden has been studied as a predictor of recurrent atrial fibrillation after atrial-fibrillation ablation, and inducible atrial fibrillation has been evaluated prospectively after PSVT ablation in patients without prior atrial fibrillation. ^[167][192]C Troponin testing and its association with adverse outcomes have been examined in retrospective SVT cohorts, reflecting ongoing attempts to avoid unnecessary investigation while identifying higher-risk presentations. ^{[136]B3b[190]C} Sleep duration and sleep disturbance have also been investigated as potential predictors of next-day ectopy and nonsustained SVT. ^[58]B2b

Evidence outside the core SVT treatment pathway should not be extrapolated directly: a pacemaker-versus-monitor substudy addressed recurrent syncope in patients with bifascicular block rather than SVT treatment, and a veterinary study evaluated mitral-valve repair in dogs with atrial fibrillation. ^[56]B2b[188] Neonatal multisystem inflammatory syndrome associated with prenatal SARS-CoV-2 exposure included cardiac involvement such as SVT, but its findings concern a distinct inflammatory neonatal condition. ^[166]

Hemodynamic and clinical complications

Supraventricular tachycardia (SVT) is often tolerated, but a rapid or sustained episode can produce hypotension, presyncope or syncope, myocardial oxygen-demand mismatch, heart-failure symptoms, and, rarely, shock; the risk is greater in patients with structural heart disease or limited cardiovascular reserve.^{[136]B3b[195]} Hemodynamic instability should be treated as an emergency rather than managed with repeated outpatient or self-administered termination attempts.^{[54]A1a[25]B2b} In stable adults, vagal maneuvers remain first-line treatment, and the modified Valsalva maneuver has been specifically evaluated against the standard technique in randomized emergency-department research.^[54]A1a[169] Carotid-sinus massage carries additional procedural concern because it may provoke bradycardia or atrioventricular block, particularly in susceptible patients; the 2025 network meta-analysis compared it with standard and modified Valsalva maneuvers and head-down deep breathing, but maneuver selection must remain clinically individualized.^[54]A1a

Syncope may occur during or after an arrhythmic episode, but recurrent syncope is not necessarily attributable to SVT alone. In a pacemaker population with bifascicular block, baseline clinical variables did not predict recurrent syncope, and syncope could recur despite pacing.^[56]B2b This supports reassessment for intermittent tachyarrhythmia, bradyarrhythmia, conduction disease, orthostatic mechanisms, and noncardiac causes when loss of consciousness persists.^[56]B2b

Myocardial injury and major adverse cardiovascular events

Troponin elevation can accompany SVT because of tachycardia-related myocardial stress, but an elevated result should not automatically be interpreted as acute coronary occlusion.^[136]B3b A large retrospective, propensity-score-matched TriNetX study examined whether troponin testing identified 30-day major adverse cardiovascular events (MACE) in emergency-department patients with SVT; the study was designed around the previously reported low overall prevalence of MACE in this population.^[136]B3b Troponin testing should therefore be guided by symptoms, ischemic electrocardiographic changes, persistent instability, and cardiovascular risk rather than by the SVT diagnosis alone.^[136]B3b This observational evidence cannot establish that selective testing is safe for every patient or exclude acute coronary syndrome when clinical findings are concerning.^[136]B3b

Treatment-related complications

Vagal maneuvers can be uncomfortable and may cause transient hypotension, dizziness, or excessive vagal slowing; the network meta-analysis evaluated conversion after single and multiple attempts and the need for rescue treatment, emphasizing that failure should prompt escalation rather than indefinite repetition.^[54]A1a Adenosine may cause brief adverse sensations and clinically important bradycardia or atrioventricular block; a prospective emergency-department study compared initial 6-mg versus 12-mg dosing while assessing both conversion and adenosine-related adverse events.^[168]

Intranasal etripamil is being developed for rapid, potentially unsupervised PSVT termination. Randomized-trial meta-analysis evaluated 70 mg against placebo for efficacy and safety, while the NODE-303 open-label study assessed repeated at-home episodes, ECG monitoring, and an optional second 70-mg dose when symptoms persisted after 10 minutes.^{[139]A1a[25]B2b} Because patients may misidentify atrial fibrillation as PSVT, NODE-303 also evaluated ventricular-rate slowing when episodes initially presumed to be PSVT were subsequently identified as atrial fibrillation.^[24]B2b Self-treatment should not delay emergency assessment for severe chest pain, dyspnea, syncope, marked hypotension, or persistent tachycardia.^{[24]B2b[25]B2b}

Ablation-related complications

Catheter ablation is used for recurrent or symptomatic AVNRT and AVRT, but complications can include vascular injury, bleeding, thromboembolic events, cardiac perforation, radiation exposure, arrhythmia recurrence, and inadvertent atrioventricular conduction-system injury; the cited ablation studies specifically assessed procedural safety and longer-term outcomes.^{[183][140]A1a} A randomized trial compared contact-force-sensing with conventional radiofrequency ablation for AVNRT/AVRT, assessing radiofrequency applications, treatment time, fluoroscopy exposure, efficacy, safety, and long-term outcomes.^[183] Pulsed-field ablation is a nonthermal technique under early investigation for PSVT, including AVNRT and AVRT with concealed or manifest accessory pathways; its systematic review evaluated acute success, follow-up success through 6 months, and procedural or postoperative adverse events.^[140]A1a The available evidence supports evaluation of safety, but does not justify assuming that pulsed-field ablation eliminates established catheter-ablation risks.^{[140]A1a[183]}

Special populations and associated arrhythmias

Pregnancy complicated by maternal arrhythmia has been associated with adverse maternal or perinatal outcomes in observational evidence, including studies evaluating preeclampsia, stillbirth, preterm delivery, and small-for-gestational-age birth; the magnitude of risk varies by arrhythmia and clinical context.^[45]B2a A large contemporary cohort specifically compared pregnancies with SVT or atrial fibrillation/flutter with pregnancies without arrhythmia and assessed cardiac and perinatal outcomes.^[195] Patients with Fontan circulation have a particularly vulnerable substrate: a meta-analysis of 1,260 pregnancies in 400 women reported a pooled maternal-arrhythmia incidence of 6.59% (95% CI 3.??–??), although the supplied abstract does not provide the complete confidence interval.^[147]B2a

Postoperative supraventricular arrhythmias—including SVT, atrial flutter, atrial fibrillation, atrial tachycardia, and junctional tachycardia—are clinically relevant after thoracoscopic lung-cancer surgery; a randomized trial evaluated electroacupuncture for arrhythmia occurring during the first 24 hours after surgery.^[47]A1b Postoperative junctional ectopic tachycardia after congenital-heart surgery can be hemodynamically consequential; a pediatric systematic review evaluated ivabradine for conversion, recurrence, bradycardia, hypotension, QT prolongation, atrioventricular block, concomitant antiarrhythmic use, and mortality.^[23]A1a Evidence for off-label ivabradine remains limited to the reviewed pediatric studies.^[23]A1a

Systemic disease and medications may modify arrhythmic risk. A prospective PsA cohort evaluated atrial tachyarrhythmia, including AF and SVT, ventricular tachyarrhythmia, and bradycardia requiring pacing over long-term follow-up.^[149] In patients with type 2 diabetes, a meta-analysis of randomized trials assessed semaglutide in relation to arrhythmic, major cardiovascular, and microvascular outcomes, but these results concern semaglutide-treated diabetes populations rather than acute SVT management.^[43]A1a A randomized study of ganglionated-plexus modification examined patients with PSVT or frequent PVCs combined with vagal bradycardia, reflecting the potential coexistence of tachyarrhythmia and clinically relevant bradyarrhythmia.^[26]A1b

Overall prognosis

The supplied evidence does not establish a single natural-history trajectory for all supraventricular tachycardias (SVTs), because the studies include heterogeneous populations: stable paroxysmal SVT (PSVT), postoperative junctional ectopic tachycardia (JET), postoperative supraventricular arrhythmia, critically ill adults, and patients with vagal bradycardia and tachyarrhythmias. ^{[10]A1b[23]A1a[26]A1b[47]A1b[57]A1b[152]C} Most contemporary studies evaluate acute conversion, treatment delivery, recurrence, or healthcare utilization rather than long-term mortality, ventricular function, or quality of life. ^{[10]A1b[55]A1b[57]A1b[169][196][197]}

For hemodynamically stable PSVT, the immediate prognosis is generally assessed by successful termination of the episode and avoidance of emergency transport or admission. Randomized trials evaluated standard versus modified Valsalva techniques in adults and children, while a device-assisted Valsalva trial evaluated whether maintaining target intrathoracic pressure improves restoration of sinus rhythm. ^{[10]A1b[57]A1b[169]} An ambulance-service stepped-wedge trial assessed whether out-of-hospital availability of a Valsalva-assist device reduced conveyance to hospital. ^[55]A1b A retrospective prehospital study from Poland evaluated Valsalva use, documented rhythm, syncope, termination, and transport decisions, but its design and the supplied abstract do not provide a definitive long-term prognosis. ^[28]B3b

Recurrence and long-term follow-up

Recurrence is an important outcome after either medical or interventional treatment, but the supplied references do not provide a pooled recurrence rate for typical AV nodal re-entry tachycardia, atrioventricular re-entry tachycardia, or focal atrial tachycardia. The TRUST study was designed as a prospective cohort integrating baseline phenotyping, imaging, procedural information, treatment response, and longitudinal follow-up to identify predictors of recurrence across cardiac arrhythmias; the supplied abstract is a design and patient-profile report rather than a results report. ^[196] A multicenter emergency-department cohort examined protocol adherence, initial adenosine dosing, alternative pharmacologic agents, and disposition in adults with stable SVT, but its retrospective design limits causal inference about long-term outcomes. ^[197]

Catheter ablation is represented in the supplied evidence by a randomized study of 110 patients with premature ventricular contractions or PSVT accompanied by vagal bradycardia. All participants underwent conventional electrophysiologic assessment and ablation of the tachyarrhythmia, followed by comparison of superior vena cava–aorta ganglionated plexus modification with control treatment. The study specifically examined heart rate and prognosis in this selected bradycardic population; its findings should not be extrapolated to unselected SVT. ^[26]A1b

Special populations

Postoperative JET after congenital heart surgery is described as frequent and potentially hemodynamically consequential in children. A 2026 systematic review and single-arm meta-analysis pooled conversion to sinus rhythm, time to conversion, recurrence, concomitant antiarrhythmic-drug use, adverse events, and all-cause mortality among children treated with oral or nasogastric ivabradine. Because the analysis was single-arm and included only five studies, comparative conclusions about prognosis remain limited. ^[23]A1a

Postoperative supraventricular arrhythmia also occurs after thoracoscopic lung-cancer surgery. A randomized trial of 77 adults assessed new-onset SVT—including atrial flutter, atrial fibrillation, atrial tachycardia, and atrioventricular junctional tachycardia—during the first 24 hours after surgery and compared electroacupuncture with control care. This endpoint describes early postoperative incidence rather than long-term recurrence or survival. ^[47]A1b

Critical illness may modify risk and outcomes. A time-dependent propensity-score study across 11 hospitals evaluated clinically significant SVT in mechanically ventilated adults exposed to dexmedetomidine, while a multicenter retrospective study examined protocolized magnesium supplementation and atrial fibrillation/flutter, tachyarrhythmia, and death within 24 hours in ICU patients. These studies address associations in critically ill populations and should not be interpreted as evidence for the natural history of outpatient PSVT. ^{[152]C[84]B2b}

Disposition, mortality, and applicability of evidence

Prehospital treat-and-discharge pathways have been studied for resolved SVT in Ontario, where paramedic records were used to describe directive utilization, operational metrics, and subsequent emergency-department use. Such data may inform short-term safety and healthcare utilization after rhythm resolution, but they do not define late recurrence risk. ^[82]B3b In children aged 0–18 years without congenital heart disease, a Nationwide Emergency Department Sample analysis evaluated insurance payer in relation to admission or transfer, inpatient length of stay, procedures, and mortality; this study primarily describes disparities in acute disposition rather than disease biology. ^[153]

Several supplied references are not directly applicable to SVT prognosis. A simulation study compared single- versus double-syringe adenosine administration in pediatric emergencies and therefore informs workflow, not natural history. ^[134]A1b An observational emergency-department study compared initial 12-mg versus 6-mg adenosine dosing in stable adult SVT, focusing on first-dose conversion and adverse effects rather than long-term outcomes. ^[168] A sex-specific retrospective study examined symptoms, acute treatment, treatment success, follow-up recommendations, and etiologic factors in women and men presenting with SVT; its findings concern presentation and care patterns rather than survival. ^[150] Studies of idiopathic ventricular fibrillation/early-repolarization syndrome, repaired pulmonary stenosis, and canine mitral-valve disease address different arrhythmia or disease populations and should not be used to estimate human SVT prognosis. ^{[73]B3b[83]B2b[188]}

Overall, the strongest current evidence supports short-term assessment of termination, hemodynamic stability, recurrence during follow-up, and need for transport or admission. Long-term prognosis remains dependent on SVT mechanism, structural or postoperative substrate, comorbidity, treatment strategy, and recurrence surveillance; the supplied references do not permit a reliable universal mortality or recurrence estimate. ^{[10]A1b[23]A1a[26]A1b[47]A1b[55]A1b[82]B3b[196][197]}

Pregnancy: risk assessment and prevention

Pregnancy-related physiological changes increase susceptibility to supraventricular tachycardia (SVT), and management should integrate maternal symptoms, hemodynamic status, fetal considerations, gestational age, and the presence of structural or congenital heart disease.^{[141]A1c[198]C} The 2023 HRS consensus provides multidisciplinary guidance for diagnosis, risk stratification, noninvasive and invasive treatment, and management of both maternal and fetal arrhythmias.^[141]A1c Evaluation should confirm the rhythm and identify potentially reversible or high-risk contributors, while involving cardiology/electrophysiology and obstetric teams when episodes are recurrent, sustained, poorly tolerated, or associated with ventricular dysfunction.^[141]A1c

In a cohort of otherwise healthy women with structurally normal hearts admitted for labor, documented SVT occurred in 76 women among 141,769 eligible pregnancies; the study evaluated prevalence, management, and obstetric outcomes.^[199] A separate retrospective study of 77 pregnancies in 75 women referred for a cardiac-obstetric clinic found that 63 pregnancies (82%) involved a previous history of paroxysmal SVT, with comparison of episode severity, management, and maternal, fetal, and neonatal outcomes against healthy controls.^[203] These findings support preconception review of women with known recurrent SVT and an individualized plan for recurrence during pregnancy.^{[141]A1c[203]}

Pre-excitation syndrome is clinically important because affected pregnant patients are more likely to develop SVT during pregnancy and delivery.^[200] In a retrospective series, pre-excitation was identified in 309 pregnancies among 280 women, representing 0.24% of 127,725 hospitalized pregnancies; outcomes were compared between pregnancies with and without SVT.^[200] In adults with congenital heart disease, clinically significant arrhythmia occurred in 15% of 172 pregnancies, with 64% of events occurring during the second trimester and sustained SVT the most common rhythm; the investigators also developed a risk score and assessed whether preconception ablation influenced antepartum arrhythmia.^[174] Fontan physiology represents a particularly high-risk population: a systematic review and meta-analysis including 400 women and 1,260 pregnancies reported a pooled maternal-arrhythmia incidence of 6.59%.^[147]B2a

Acute treatment during pregnancy

For stable SVT, initial management may include vagal stimulation, followed by pregnancy-compatible pharmacotherapy when required, according to specialist guidance.^[141]A1c In a small emergency-department series of 15 pregnant patients, three converted spontaneously, five responded to vagal stimulation, and four responded to esophageal pacing; one required verapamil and another responded to labetalol after failure of vagal stimulation and pacing.^[198]C Because this was a small retrospective series, its treatment-success rates should not be generalized.^[198]C

Hemodynamic instability warrants prompt electrical cardioversion rather than withholding treatment because of pregnancy.^{[141]A1c[201]} A multicentre UK/Ireland study reported 29 direct-current cardioversions in 27 pregnant women, with no maternal deaths; 63% had pre-existing heart disease, and 70% initially presented to emergency departments.^[201] The study was designed to assess maternal and fetal outcomes after cardioversion and reinforces that clinically indicated cardioversion is an available treatment in pregnancy.^[201]

Catheter ablation is generally reserved for drug-refractory, poorly tolerated, recurrent, or incessant tachycardia when the maternal benefit outweighs procedural risk.^[141]A1c Incessant focal atrial tachycardia can cause tachycardia-induced cardiomyopathy, and a 2024 systematic review evaluated ablation during pregnancy, particularly non-fluoroscopic navigation approaches, as an alternative to ongoing drug exposure.^[142]B2a Case-based literature also describes three-dimensional intracardiac-ultrasound-guided radiofrequency ablation for pregnancy-associated SVT with favorable reported maternal and neonatal outcomes, although such evidence remains limited to individual reports.^[89]C4 A 2026 narrative review similarly addressed electrical cardioversion and catheter ablation, noting that delayed rhythm control may contribute to maternal cardiovascular instability and fetal distress, while emphasizing that the evidence base is largely observational and case-based.^[94]D5

Outcomes and prevention of recurrence

Available observational evidence links maternal arrhythmias with clinically relevant pregnancy outcomes, but estimates vary by population and arrhythmia type.^{[45]B2a[199][202]C[203]} Prospective registry data from Colombia characterized tachyarrhythmias and bradyarrhythmias and assessed cardiac events including pulmonary edema, symptomatic sustained arrhythmia requiring therapy, stroke, cardiac arrest, and maternal death.^[202]C Large retrospective and meta-analytic studies have additionally examined preeclampsia, stillbirth, preterm delivery, and small-for-gestational-age neonates in pregnancies complicated by arrhythmia.^[45]B2a[195] These data support coordinated antenatal surveillance rather than assuming that SVT is uniformly benign.^{[45]B2a[195][199][202]C[203]}

Prevention should include preconception electrophysiology review for recurrent SVT, pre-excitation, adult congenital heart disease, or Fontan circulation; correction of individualized triggers; and a documented plan for emergency evaluation and rhythm treatment.^{[141]A1c[147]B2a[174][200]} Preconception ablation may be considered in selected patients with recurrent symptomatic SVT, although the available congenital-heart-disease study specifically evaluated its effect on subsequent antepartum arrhythmia and does not establish benefit for all patients.^[174]

Other special populations and exposures

Clenbuterol, a potent beta-2 agonist misused by athletes and bodybuilders, has been associated with adverse events in 24 athletes across 23 case reports or case series identified in a systematic review; avoidance is an important prevention measure in patients vulnerable to tachyarrhythmia.^[143]C4 Wearable chest-strap monitors and smartwatches detected clinically relevant paroxysmal arrhythmias in a 10-athlete case series when conventional testing repeatedly failed to document episodes, suggesting a possible adjunct for symptom-rhythm correlation rather than a substitute for clinical ECG confirmation.^[90]C4

COVID-19 vaccination during pregnancy was assessed in a 2024 systematic review, which concluded that vaccination was generally safe for pregnant individuals and their newborns.^[144]D5 This prevention strategy should not be conflated with treatment of SVT. Conversely, a single-center series of 15 neonates with multisystem inflammatory syndrome associated with prenatal maternal SARS-CoV-2 reported cardiac involvement in all neonates, including SVT or persistent sinus abnormalities; causation and generalizability remain uncertain.^[166]

In nonpregnant emergency-department populations, intravenous adenosine remains standard first-line therapy for stable SVT, although transient post-conversion sinus pauses may occur; a 2026 retrospective study examined whether age, body mass index, and symptom duration predicted pause duration.^[159] This evidence is not pregnancy-specific and should not override pregnancy-focused consensus recommendations.^[141]A1c